Mostrando 4 resultados de: 4
Subtipo de publicación
Article(4)
Área temáticas
Enfermedades(4)
Medicina y salud(2)
Farmacología y terapéutica(1)
Problemas sociales y servicios a grupos(1)
Origen
scopus(4)
Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusNimotuzumab for the treatment of patients with malignant glioma. Comparison between pre-registration and post-approved studies
ArticleAbstract: Nimotuzumab is a monoclonal antibody targeted against the epidermal growth factor receptor approvedPalabras claves:And High-grade glioma, Controlled clinical studies, nimotuzumab, Postmarking studies, Target therapiesAutores:Aliuska Frías, Carmen Elena Viada, García L., Luaces P.L.o., Mabel Álvarez, Macías A.E., Santiesteban Y., Saurez G., Tania CrombetFuentes:scopusSafety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: A dose-escalation phase I study trial
ArticleAbstract: Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effectivPalabras claves:Human epidermal growth factor receptor, Immunogenicity, Prostate cancer, safety, Therapeutic vaccineAutores:Aira L.E., Bárbara Wilkinson, Caballero I., Casacó Parada A.R., Coba K., González J.G., González N., Lavastida A., Luaces P.L.o., Macías A.E., Mazorra Z., Mesa M., Popa X., Rivero J., Sanchez B., Santiesteban Y., Suárez E., Tania Crombet, Troche M.Fuentes:scopusQuality of life assessment as a pbkp_redictor of survival in cancer
ArticleAbstract: The quality of life and survival are variables to take into account in the clinical trial of oncologPalabras claves:clinical trials, Oncology, quality of life, SurvivalAutores:Aliuska Frías, Ballesteros J., Bouza-Herrera C.N., Carmen Elena Viada, García L., Mabel Álvarez, Martha M. Fors-López, Ramos M., Santiesteban Y.Fuentes:scopus